Market Place
Sourcing Support
GenSight Biologics Approves All Resolutions at General Meeting
13 May 2025 //
BUSINESSWIRE
GenSight Biologics Annual General Meeting on May 13, 2025
23 Apr 2025 //
BUSINESSWIRE
GenSight Biologics Files 2024 Universal Registration Document
08 Apr 2025 //
BUSINESSWIRE
GenSight Biologics Reports Cash Position as of March 31, 2025
07 Apr 2025 //
BUSINESSWIRE
GenSight Biologics Confirms Full-Year 2024 Financial Results
19 Mar 2025 //
BUSINESSWIRE
GenSight Biologics Updates LUMEVOQ® at NANOS 2025
17 Mar 2025 //
BUSINESSWIRE
GenSight Reports Estimated Full-Year 2024 Financial Results
27 Feb 2025 //
BUSINESSWIRE
GenSight Reports 5-Year LUMEVOQ Gene Therapy Data From REFLECT Study
12 Feb 2025 //
BUSINESSWIRE
GenSight Reports Cash Position & Provides Business Update
23 Jan 2025 //
BUSINESSWIRE
GenSight Reports Long Term Success In Gene Therapy Treatment
15 Jan 2025 //
BUSINESSWIRE
GenSight Biologics Updates on Regulatory Talks and Financials
18 Dec 2024 //
BUSINESSWIRE
GenSight Submits Lumevoq® Dossier for Early Access in France
13 Nov 2024 //
BUSINESSWIRE
GenSight Biologics Publishes Meta-Analysis for ND4-LHON
28 Oct 2024 //
BUSINESSWIRE
GenSight Biologics Reports Cash Position And Business Update
24 Oct 2024 //
BUSINESSWIRE
GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024
17 Oct 2024 //
BUSINESSWIRE
GenSight Reports H1 2024 Results Provides Business Updates
23 Sep 2024 //
BUSINESSWIRE
GenSight Reports June 30 Cash Position And Provides Business Update
22 Jul 2024 //
BUSINESSWIRE
GenSight Biologics Launches Newsletter for Retail Investors
11 Jul 2024 //
BUSINESSWIRE
GenSight Biologics Renegotiates Finances And Provides Operational Updates
20 Jun 2024 //
BUSINESSWIRE
GenSight Bio: Upcoming Medical Meetings & Stakeholder Presentations
04 Jun 2024 //
BUSINESSWIRE
GenSight Biologics Appoints William Monteith to its Board of Directors
03 Jun 2024 //
BUSINESSWIRE
GenSight Biologics Announces its 2024 Financial Calendar
04 Apr 2024 //
BUSINESSWIRE
GenSight Biologics Reports Cash Position as of March 31, 2024
04 Apr 2024 //
BUSINESSWIRE
GenSight Biologics Reports Full Year 2023 Consolidated Financial Results
22 Mar 2024 //
BUSINESSWIRE
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ
20 Mar 2024 //
BUSINESSWIRE
GenSight Biologics Announces Initial Results from New Meta-Analyses
12 Mar 2024 //
BUSINESSWIRE
GenSight Announces Update on Data from Early Access Programs of LUMEVOQ
06 Mar 2024 //
BUSINESSWIRE
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024
04 Mar 2024 //
BUSINESSWIRE
GenSight Biologics Announces Presentation of LUMEVOQ Efficacy Data
15 Mar 2023 //
BUSINESSWIRE
GenSight Biologics Confirms Efficacy and Safety of Bilateral LUMEVOQ
13 Mar 2023 //
BUSINESSWIRE
GenSight Biologics Announces Publication of LUMEVOQ Safety Data
09 Mar 2023 //
BUSINESSWIRE
GenSight Announces 1 Year Safety Efficacy Signals from PIONEER PI/II of GS030
13 Feb 2023 //
BUSINESSWIRE
GenSight Biologics Strengthens Its Team to Support the Launch of LUMEVOQ
12 Sep 2022 //
GENSIGHT-BIOLOGICS
GenSight Biologics reports 5 years’ data showing sustained efficacy and safety
20 Jul 2022 //
BUSINESSWIRE
GenSight Biologics Announces Publication of Study of the Impact of LHON Disease
18 May 2022 //
BUSINESSWIRE
GenSight seeks cash as gene therapy runway enters final year
09 Apr 2022 //
FIERCEBIOTECH
GenSight Biologics Reports Clinically Meaningful Vision Improvement
24 Jan 2022 //
BUSINESSWIRE
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ
14 Dec 2021 //
BUSINESSWIRE
GenSight Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ Injections
13 Dec 2021 //
BUSINESSWIRE
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes
29 Nov 2021 //
BUSINESSWIRE
GenSight Biologics to Host Key Opinion Leader Webcast on LUMEVOQ in US
22 Nov 2021 //
BUSINESSWIRE
GenSight Reports Second Patient Case Showing Significant Visual Recovery
17 Nov 2021 //
BUSINESSWIRE
Hiccup in manufacturing will cause GenSight to repeat the process
04 Nov 2021 //
ENDPTS
FDA Grants FTD to GenSight`s Optogenetic Therapy GS030 for Retinitis Pigmentosa
12 Oct 2021 //
BUSINESSWIRE
GenSight Biologics Announces FDA Grant of Fast Track Designation
12 Oct 2021 //
BUSINESSWIRE
GenSight Announces Publication of Review of Gene Therapy Trials for LHON
06 Oct 2021 //
BIOSPACE
GenSight Biologics Announces +ve Data Safety Review of PIONEER Ph I/II GS030
14 Sep 2021 //
SHARECAST
GenSight Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects
09 Sep 2021 //
BUSINESSWIRE
MHRA grants promising innovative medicine status to GenSight’s Lumevoq
08 Sep 2021 //
PHARMABIZ
UK MHRA Grants GenSight Biologics’ LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine Designation
07 Sep 2021 //
BUSINESSWIRE
GenSight Biologics Announces Publication of RESTORE Study Data
31 Aug 2021 //
BUSINESSWIRE
GenSight Biologics Announces Approval of the LUMEVOQ® Cohort
06 Jul 2021 //
BUSINESSWIRE
GenSight granted Temporary Cohort Use Authorization (ATUc) for LUMEVOQ
06 Jul 2021 //
BUSINESSWIRE
GenSight announces positive results from phase III REFLECT trial of Lumevoq
02 Jul 2021 //
PHARMABIZ
GenSight`s gene therapy mystery continues
30 Jun 2021 //
ENDPTS
GenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial
30 Jun 2021 //
BUSINESSWIRE
GenSight Biologics appoints Marion Ghibaudo as Technical Director
10 Jun 2021 //
BUSINESSWIRE
GenSight Biologics Appoints Marion Ghibaudo as Chief Technical Officer
10 Jun 2021 //
PRESS RELEASE
GenSight Biologics Announces Nature Medicine Case Report Showing
25 May 2021 //
GENSIGHT-BIOLOGICS
GenSight Biologics Announces Nature Medicine Case Report Showing Visual
24 May 2021 //
BUSINESSWIRE
